Zenas BioPharma reported that its Phase 2 MoonStone trial of obexelimab in relapsing multiple sclerosis achieved a 95% relative reduction in new gadolinium‑enhancing T1 lesions versus placebo over weeks 8 and 12, with a highly significant p‑value of 0.0009. The 116‑patient study found only two new lesions in the obexelimab group compared with 19 in the placebo arm, and a 40% reduction in serum neurofilament light at week 24, while Expanded Disability Status Scale scores remained stable.
The magnitude of the lesion reduction is unprecedented for a non‑depleting B‑cell modulator and demonstrates obexelimab’s potent anti‑inflammatory activity. Sustained suppression through week 12, coupled with a durable neurofilament signal, suggests that the drug can both halt acute inflammatory activity and protect against ongoing neuronal injury, addressing unmet needs in relapsing multiple sclerosis.
These clinical results reinforce Zenas’s strategy to file a Biologics License Application for immunoglobulin G4‑related disease in the second quarter of 2026. The dual‑indication potential—multiple sclerosis and IgG4‑related disease—positions obexelimab as a unique, subcutaneously administered therapy that could compete with established anti‑CD20 agents while offering a distinct mechanism of action.
Founder and CEO Lonnie Moulder said the data “provide strong evidence of the deep and sustained inhibitory mechanism of obexelimab and further validate the potential for obexelimab to become a meaningful therapy across multiple autoimmune diseases.” His comments underscore the company’s confidence in the drug’s broader therapeutic promise.
Analysts responded positively to the trial, noting that the robust efficacy and safety profile strengthen the likelihood of regulatory approval and future commercial success. The announcement has been viewed as a significant step forward for the company’s pipeline.
Zenas’s financial position allows it to fund operations through the fourth quarter of 2026, but the company will likely seek additional capital to support the upcoming BLA filing and potential commercialization. The strong trial outcomes are expected to improve investor confidence and facilitate future financing rounds.
With the BLA filing slated for Q2 2026, obexelimab’s market entry could open a new revenue stream and expand the company’s footprint in the autoimmune disease space, potentially accelerating the development of additional indications.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.